The most-clicked news item for for Friday/Saturday was a Pharmalot piece about Pfizer.  In “Pfizer is Liable for Harm Caused by a Generic Version of its Drug: Court,” Ed Silverman explains how the Alabama Supreme Court has upheld a very controversial ruling that would allow Pfizer to be held legally liable for drug injuries caused by a generic competitor’s version of Pfizer’s Reglan.  

The second most popular news item is also from WSJ Pharmalot.  In “Unfair!! Eisai Sues FDA to Regain ‘Lost’ Marketing Time for its Drugs,” Eisai is suing the FDA because it claims that delays in approving two of their drugs has caused them to lose valuable marketing time.  Both Belviq and Fycompa, which are controlled substances, could not be marketed until the DEA was able to list them.  

The third most-clicked news link was “Amgen in talks with Repligen to equip 'facility of the future.’ “  Amgen is planning to create a new Singapore biologics plant with fermentation and chromatography technology with help from Repligen.

The fourth most-clicked link was “Gilead says wins favorable ruling on hep C drug.”  An arbitration panel has ruled in Gilead’s favor on Roche’s claim that Gilead’s Sovaldi infringed on a patent that would be rightly theirs through a 2004 agreement with Pharmasset.